Dapagliflozin for heart failure according to body mass index: the DELIVER trial.

MLA

Adamson, Carly, et al. “Dapagliflozin for Heart Failure According to Body Mass Index: The DELIVER Trial.” European Heart Journal, vol. 43, no. 41, Nov. 2022, pp. 4406–17. EBSCOhost, https://doi.org/10.1093/eurheartj/ehac481.

APA

Adamson, C., Kondo, T., Jhund, P. S., Boer, R. A. de, Honorio, J. W. C., Claggett, B., Desai, A. S., Gamba, M. A. A., Habeeb, W. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Langkilde, A. M., Lindholm, D., Bachus, E., Litwin, S. E., Martinez, F., Petersson, M., & Shah, S. J. (2022). Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), 4406–4417. https://doi.org/10.1093/eurheartj/ehac481

Chicago

Adamson, Carly, Toru Kondo, Pardeep S Jhund, Rudolf A de Boer, Jose Walter Cabrera Honorio, Brian Claggett, Akshay S Desai, et al. 2022. “Dapagliflozin for Heart Failure According to Body Mass Index: The DELIVER Trial.” European Heart Journal 43 (41): 4406–17. doi:10.1093/eurheartj/ehac481.